Document is current
Any future updates will be listed below
-
Authors
Lu, Yongjin
Shi, Zhiqiang
Zhao, Qiuchen
Bi, Zhao
Sun, Xiao
Wang, Chunjian
Jia, Ruijie
Zheng, Junsheng
Sun, Jing
Wang, Yongsheng
Qiu, Pengfei
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82172873, 82172873, 82172873)
National Natural Science Foundation of International (Regional) Cooperation and Exchange Project (W2421095, W2421095, W2421095)
Jinan Science and Technology Plan (202430063, 202430063, 202430063)
National Health Commission of China’s Innovative Drug Post-Marketing Clinical Research Program (WKZX2023CX050001, WKZX2023CX050001, WKZX2023CX050001)
- License Information
-
More Information
Article History
Received: 5 August 2024
Accepted: 23 April 2025
First Online: 13 May 2025
Declarations
:
: This study was registered with the Shandong Cancer Hospital Ethics Committee (No.SDTHEC20230324) and approved by the institutional review board of participating center. Written informed consent was obtained from all patients before participation in the study. The study protocol was approved by ethics committees, and the study was undertaken in full accordance with the Declaration of Helsinki.
: The authors declare no competing interests.
